FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 33 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses June 5, 2024 NHS England change of chief executive – what does it mean... August 19, 2021 Load more HOT NEWS Seven Centres to form new Cancer Research UK network Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal... Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...
